Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 455 Grand Union Boulevard SOMERVILLE MA 02145 |
Tel: | 1-621-7347 |
Website: | https://www.bluebirdbio.com |
IR: | See website |
Key People | ||
Andrew Obenshain President, Chief Executive Officer, Director | Christopher Krawtschuk Chief Financial Officer | Thomas J. Klima Chief Commercial and Operating Officer |
Richard A. Colvin Chief Medical Officer | Joseph D. Vittiglio Chief Business and Legal Officer |
Business Overview |
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD). |
Financial Overview |
For the nine months ended 30 September 2023, bluebird bio Inc revenues increased from $3.5M to $21.7M. Net loss decreased 59% to $123.4M. Revenues reflect Biological product segment increase from $71K to $19.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$3.95 to -$1.12. |
Employees: | 323 as of Jan 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1.39M as of Sep 30, 2023 |
Annual revenue (TTM): | $21.73M as of Sep 30, 2023 |
EBITDA (TTM): | -$326.70M as of Sep 30, 2023 |
Net annual income (TTM): | -$91.17M as of Sep 30, 2023 |
Free cash flow (TTM): | -$286.43M as of Sep 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 190,355,471 as of Dec 19, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |